A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen

An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.

Inclusion Criteria:

• Patient is Human immunodeficiency virus (HIV) positive
• Patient is taking an MK0518 (Raltegravir) containing regimen
• Patient has not had any changes to his/her antiviral regimen in the last 2 weeks
• Patient who is of reproductive potential agrees to use an acceptable method of birth control
• Patients baseline health is stable

Exclusion Criteria:

• Patient has a history of stroke or chronic seizures.
• Patient has a history of gastric bypass surgery
• Patient is pregnant of breastfeeding
• Patient consumes excessive amounts of caffeinated beverages daily
• Patient has had major surgery, donated blood, or participated in another investigational study in the past 4 weeks